What is William Blair’s Estimate for APLS Q3 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at William Blair increased their Q3 2025 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($0.15) per share for the quarter, up from their previous forecast of ($0.17). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.73) EPS and Q1 2026 earnings at $0.02 EPS.

A number of other equities research analysts also recently issued reports on the company. Royal Bank of Canada lowered their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research report on Monday, March 3rd. Wedbush reduced their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group lowered their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Finally, Scotiabank increased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a research report on Wednesday. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $45.59.

Apellis Pharmaceuticals Trading Down 11.3 %

APLS stock opened at $19.97 on Friday. Apellis Pharmaceuticals has a 52 week low of $19.76 and a 52 week high of $57.85. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The business has a fifty day simple moving average of $26.22 and a 200-day simple moving average of $29.05.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. During the same quarter last year, the firm posted ($0.73) earnings per share. Apellis Pharmaceuticals’s revenue was up 45.2% on a year-over-year basis.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of APLS. Xponance Inc. grew its position in shares of Apellis Pharmaceuticals by 5.6% during the 4th quarter. Xponance Inc. now owns 14,072 shares of the company’s stock valued at $449,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the last quarter. Woodline Partners LP raised its position in shares of Apellis Pharmaceuticals by 0.5% during the 4th quarter. Woodline Partners LP now owns 189,477 shares of the company’s stock worth $6,046,000 after purchasing an additional 913 shares during the period. Signaturefd LLC lifted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after purchasing an additional 918 shares during the last quarter. Finally, Toronto Dominion Bank boosted its position in Apellis Pharmaceuticals by 4.2% during the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock valued at $739,000 after purchasing an additional 1,022 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 6,247 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $179,288.90. Following the completion of the sale, the chief executive officer now directly owns 307,415 shares in the company, valued at approximately $8,822,810.50. The trade was a 1.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now owns 55,560 shares in the company, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,054 shares of company stock valued at $1,952,719. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).